Recent Updates
Recently added Catalysts

Platinol

Phase 1

Carcinoma, Transitional Cell | Small molecule | Oncology |Eli Lilly and Company|Last Updated: Aug 29, 2006

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment61

FDA Designations

No designations recorded

Clinical trial landscape

Platinol · 1 trial · 1 indication

Phase 1 1
NCT00101842Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder CancerCarcinoma, Transitional Cell
COMPLETED61 Analytics
PHASE1COMPLETED
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
Carcinoma, Transitional Cell
NCT0010184261
Unlock trial analytics

Study Endpoints

Primary Endpoints

Toxicity will be measured by standard grading methods.

Secondary Endpoints

Response will be measured by Response Evaluation Criteria in Solid Tumors (RECIST).
Duration of response is defined as time from first objective assessment of CR or PR to first time of progression or death from any cause.
Time to progressive disease is defined as time from enrollment to first date of disease progression.
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
PemetrexedDRUG -
GemcitabineDRUG -
PlatinolDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Biopsy-proven metastatic bladder cancer * No prior chemotherapy for metastatic disease except before or after surgery, which was completed 6 months before enrollment * Prior radiation allowed, if it is not the only site of measurable disease and if completed 3 weeks before enr...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Platinol

What is Platinol used for in Carcinoma, Transitional Cell?

Platinol is a small molecule oncology drug being studied for the treatment of Carcinoma, Transitional Cell, which is a type of bladder cancer. It is currently in Phase 1 clinical development as an investigational therapy for this condition.

Who makes Platinol?

Platinol is being developed by Eli Lilly and Company, which is publicly traded under the ticker symbol LLY on the stock market. The company is conducting clinical research on this drug for oncology indications.

What phase is Platinol in?

Platinol is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial for Platinol has been completed.

What clinical trials is Platinol in?

Platinol has one completed clinical trial registered under NCT00101842, titled 'Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer.' This Phase 1 study enrolled 61 participants in the United States.

Is Platinol FDA approved?

Platinol is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Carcinoma, Transitional Cell. The drug has not completed the clinical trial process required for regulatory approval.